A further $1 per share could be paid if another Poseida product enters phase-three clinical trials for autoimmune diseases.
Kristin Yarema, Poseida’s president and CEO, highlighted the synergy between the two companies. “We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future programs,” Yarema said.
Roche to acquire Poseida Therapeutics : Roche’s Broader Acquisition Strategy
This acquisition follows Roche’s recent move to buy Carmot Therapeutics, a developer of obesity and diabetes treatments, for up to $3.1 billion. That deal, announced in December 2023, was completed in January.
Both Roche and Poseida declined to provide additional comments regarding the deal.
